Lozid

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lozid

Lozid is a fixed-dose combination medication for the management of essential hypertension (high blood pressure). Its design integrates two distinct active components into a single oral tablet, streamlining treatment for patients whose blood pressure is not adequately controlled by monotherapy. This approach is rooted in the principle that combining two agents with different mechanisms often provides superior efficacy in blood pressure reduction.

Property Description
Active ingredient Losartan potassium, Hydrochlorothiazide (HCTZ)
Form Oral tablet (typically film-coated)
Pharmacological class Combination Antihypertensive Agent
Common use Essential Hypertension (High Blood Pressure)
Origin Synthetic chemical compounds

Dual Composition: Losartan Potassium and Hydrochlorothiazide

Lozid is classified as a Combination Antihypertensive Agent because it unites two powerful, synthetic chemical entities. It contains the active ingredient Losartan potassium, which is an Angiotensin II Receptor Blocker (ARB), and Hydrochlorothiazide (HCTZ), which is a Thiazide diuretic.

This dual-class composition is a recognized therapeutic strategy for lowering blood pressure more effectively than monotherapy. The combination of an ARB and a diuretic is a standard method for lowering blood pressure. This approach provides a way to achieve blood pressure goals by combining these two classes of medicine.


How the Combination Provides Better Blood Pressure Control

The rationale for combining these agents is to produce a synergistic effect, meaning their parallel actions offer a greater and more reliable blood pressure reduction than either agent could achieve individually. This enhanced strategy is intended for adults whose high blood pressure has proven resistant to single-drug therapy.

The Losartan component works on the vascular system to promote vessel relaxation, while the Hydrochlorothiazide component acts on the kidneys to reduce excess fluid volume. This combination has therapeutic value in treating hypertension. This indicates that the combination is an established choice in managing elevated blood pressure, typically prescribed when a patient needs more intensive control of their blood pressure.

What side effects are possible with Lozid?

Possible Side Effects and Safety Information

Lozid (Linezolid) is associated with several well-documented adverse reactions, some of which are serious and require monitoring. The most frequently reported adverse effects (common) include diarrhea, headache, nausea, vomiting, and anemia.

Serious and Clinically Significant Reactions

Myelosuppression: This involves the suppression of bone marrow, leading to conditions like thrombocytopenia (low platelet count), anemia, and neutropenia (low white blood cell count). The risk is associated with treatment duration, particularly when therapy extends beyond two weeks. Weekly monitoring of complete blood counts is advised during treatment.

Neuropathies: Peripheral neuropathy (numbness, tingling, or weakness) and optic neuropathy (potential for visual impairment, including blurred vision and visual field defects) have been reported, primarily in patients treated for periods longer than 28 days. Prompt ophthalmic evaluation is recommended if any visual symptoms occur.

Serotonin Syndrome: Due to its mild, reversible Monoamine Oxidase Inhibitor (MAOI) properties, Lozid can cause a severe condition called Serotonin Syndrome when used concomitantly with serotonergic drugs, such as certain antidepressants and opioid pain medications. Symptoms include mental status changes, hyperreflexia, and fever. The co-administration of these drug classes is generally avoided.

Lactic Acidosis and CDAD: Other significant reactions include Lactic Acidosis and Clostridium difficile-associated diarrhea (CDAD), which can range from mild diarrhea to fatal colitis. All patients who develop persistent or significant diarrhea should be evaluated for CDAD.

Safety Considerations

The medication is not approved for use in Gram-negative infections and was associated with a higher mortality rate in a clinical study of patients with catheter-related bloodstream infections. Caution is advised when prescribing to patients with pre-existing myelosuppression, severe renal or moderate to severe hepatic impairment, or in those taking medications that affect blood pressure due to potential interactions. For patients with diabetes, symptomatic hypoglycemia (low blood sugar) has been reported.

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information

The official overdose profile for Lozid is based on the acute effects of its two components. Documented overdose presentations involve signs related to pronounced effects on the cardiovascular system and fluid balance.

Overdose Scope

Classification Documented Overdose Presentation
Primary Manifestations Severe Hypotension (low blood pressure) and changes in heart rhythm, often Tachycardia (rapid heartbeat).
Physiological Effects Acute Dehydration, Volume Depletion, and Electrolyte Disturbances, such as Hypokalemia (low potassium).
Neurological/GI Effects Somnolence (drowsiness), Lethargy, Nausea, and Vomiting have been documented.

Required Emergency Action

Overdose is classified by regulators as potentially leading to severe outcomes, including profound hypotension, cardiac arrhythmias, and coma. Therefore, immediate medical attention must be sought, or a poison control center contacted, for any known or suspected overdosage. Hospital monitoring is required for assessment and care.

Management is strictly defined as symptomatic and supportive treatment, prioritizing the correction of fluid and electrolyte imbalances. Regulatory documents also state that no specific antidote is known for the Losartan component, and hemodialysis is not effective for removing Losartan or its active metabolite.

This structure details the serious risks associated with acute, excessive effects—severe volume loss and low blood pressure—which necessitate immediate medical intervention focused on correcting the documented physiological imbalances.

Therapeutic Uses of Lozid

What Lozid Treats: Main Uses and Benefits

Lozid is an oral medication containing indapamide, a thiazide-like diuretic primarily used to manage cardiovascular and circulatory conditions. It acts by promoting the elimination of excess salt and water through the kidneys while also exerting a direct effect on the blood vessels.

Management of Hypertension

The primary use of Lozid is the treatment of essential hypertension (high blood pressure). In patients with hypertension, the medication helps to lower blood pressure levels into a target range. By reducing the pressure against which the heart must pump, it assists in the long-term management of cardiovascular health.

Lozid is effective both as a standalone treatment (monotherapy) and in combination with other antihypertensive agents. Because it works differently than other classes of blood pressure medications, such as ACE inhibitors or beta-blockers, it is often used to provide an additive effect in stabilizing blood pressure.

Treatment of Edema

Lozid is also utilized to treat edema, which is the swelling caused by excessive fluid trapped in the body's tissues. This fluid retention is often associated with underlying conditions such as heart failure. By increasing the production of urine, the medication helps the body shed surplus fluid, which can relieve symptoms like swelling in the ankles, feet, or legs, and reduce the overall workload on the heart.

Key Benefits

  • Vascular Protection: Beyond its diuretic effect, indapamide has a unique property of improving the elasticity of the arteries and reducing peripheral vascular resistance. This helps the blood flow more easily throughout the body.
  • Metabolic Neutrality: At standard therapeutic doses, Lozid is generally considered to have a minimal impact on blood glucose and cholesterol levels, making it a viable option for patients who need to monitor their metabolic health.
  • Long-Lasting Action: The medication is designed to provide consistent blood pressure control over a 24-hour period, allowing for a steady therapeutic effect with once-daily administration.

Regulatory References

  1. NIH DailyMed Overview of Losartan Potassium and Hydrochlorothiazide

Eligibility and Restrictions for Use

Who can and cannot use Lozid? — Official Regulatory Information

Lozid (Linezolid) is an antibiotic approved for use in adults and pediatric patients to treat infections caused by specific susceptible Gram-positive bacteria.

Contraindicated (Should Not Be Used)

Lozid is strictly contraindicated and must not be used by patients with:

  • A known hypersensitivity or allergy to Linezolid or any of its components.
  • Those currently taking or who have taken any Monoamine Oxidase Inhibitors (MAOIs) within the last two weeks.

Use with Restrictions and Special Caution

Use is restricted in patients with certain conditions, including uncontrolled hypertension, specific psychiatric conditions like bipolar depression, or pheochromocytoma. In these cases, Lozid may only be administered if facilities for close observation and blood pressure monitoring are available. The drug is not recommended for treating Gram-negative infections.

Special Populations

  • Pediatric Patients: Use in children and adolescents under 18 years is not recommended by some regulatory bodies unless clearly necessary, though it is approved for use in the U.S. based on age and weight.
  • Pregnancy/Lactation: It should not be used during pregnancy unless the potential benefit outweighs the risk. Breastfeeding must be discontinued prior to and throughout treatment.
  • Renal/Hepatic Impairment: Use in patients with severe kidney or liver impairment requires special caution and should only proceed if the expected benefit is greater than the theoretical risk, due to the accumulation of metabolites.

What should I know about interactions with other medicines?

Lozid's interaction profile is categorized by the actions of its two components, Losartan and Hydrochlorothiazide, and is structured exclusively according to official regulatory documentation.

A formal restriction exists for co-administration with Aliskiren, which is strictly contraindicated in patients with a diagnosis of diabetes mellitus or with moderate to severe renal impairment. Combining Lozid with other agents that block the Renin-Angiotensin System, such as ACE inhibitors, is documented to increase the risk of severe hypotension and hyperkalemia due to an additive pharmacodynamic effect. The co-administration of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 inhibitors, is also officially associated with an increased risk of renal impairment and a reduction in the drug's intended effect.

Interactions affecting plasma concentration are reported through pharmacokinetic studies. Fluconazole and Cimetidine have been shown to increase the systemic exposure of the Losartan component, while Phenobarbital may decrease the exposure of Losartan and its active metabolite. Furthermore, the co-administration of Lithium is documented to reduce its clearance, leading to a risk of toxicity.

To mitigate physical absorption interference, a mandatory timing separation rule is specified for co-administration with bile acid sequestrants like Cholestyramine or Colestipol: Lozid must be taken 4 hours before or 4 to 6 hours after the sequestrant to ensure proper absorption of the Hydrochlorothiazide component.

Mechanism of Action

How Lozid Works

Lozid exerts its action by interfering with fundamental metabolic processes necessary for bacterial viability. The drug's mechanism involves disrupting the cellular components required for bacterial replication, resulting in a systemic reduction of the bacterial population.

Blocking the Bacterial Ribosome and Protein Factory

Lozid functions as an inhibitor by binding specifically to the 23S ribosomal RNA subunit, which is part of the bacterium's 50S ribosomal subunit. This precise molecular interaction physically prevents the formation of the 70S initiation complex, the critical starting block for all protein synthesis. This blockade of the ribosomal machinery prevents the synthesis of the enzymes and structural proteins critical for bacterial proliferation.

Disrupting Cellular Replication Cascades

This inhibition of the protein synthesis initiation step represents an upstream block in the entire cascade of bacterial genetic expression and metabolism. This pathway interruption limits the ability of the bacterial population to expand and multiply, resulting in a quantifiable change in the concentration of bacteria within the biological system. This mechanism operates by suppressing the critical components of the pathogen's viability, which contributes to the overall suppression of the bacterial metabolic state.

Dosage and Administration Information

Lozid (linezolid) is administered via the oral route (tablets or suspension) or by intravenous (IV) infusion. The full prescribed course of treatment, typically lasting 10 to 28 consecutive days, must be completed.

Administration Guidelines

  • Dosing Frequency: Lozid must be taken on a regular schedule to maintain consistent blood levels. For adults and adolescents (12 years and older), the dose is typically 600 mg every 12 hours.
  • Pediatric Dosing: For children (birth through 11 years), the recommended dose is generally 10 mg/kg every 8 hours, reflecting age-specific clearance rates. Neonates (under 7 days old) may be started on an every-12-hour schedule before moving to every 8 hours by one week of age.
  • With or Without Food: The medicine may be administered without regard to the timing of meals.
  • Oral Suspension Preparation: The liquid suspension must be gently mixed by inverting the bottle 3 to 5 times before measuring each dose; do not shake.
  • IV Administration: Intravenous infusion should be administered slowly over a period of 30 to 120 minutes. IV bags should not be used in series connections, and additives must not be introduced into the solution.

Missed Dose Procedure

If a dose is missed, take it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular schedule should be continued. Do not take a double dose to compensate for a missed dose.

Switching between the IV and oral formulations does not require a dose adjustment because linezolid has approximately 100% oral bioavailability.

Recent Clinical Evidence

Research evidence / Overview of studies for Lozid


Evidence for use in Community-Acquired Pneumonia (CAP)

This section will summarize the clinical trials and observational studies that have investigated the use of Lozid in adults and children with Community-Acquired Pneumonia (CAP), focusing on how different study types examined Lozid in this infection.

Lozid has been evaluated in multiple clinical trials and observational studies to understand the observations in treating CAP. The research has primarily focused on adults hospitalized with more severe CAP, often in trials where other medicines were also evaluated. Studies monitored patient outcomes related to systemic or functional imbalance and acute changes during the treatment period. Findings describe patterns observed in the trials, with the data showing how Lozid was observed in the studies when certain other medicines were also evaluated for CAP. However, results apply only to the specific populations studied, and certainty remains low regarding Lozid in milder cases.


Evidence for use in Complicated Skin and Soft Tissue Infections (cSSTI)

This section will outline the research evidence, including key comparative trials, that has evaluated Lozid in studies involving patients with Complicated Skin and Soft Tissue Infections (cSSTI), explaining the type of evidence available for how it was studied against common causative bacteria.

Lozid was evaluated in clinical trials in studies involving cSSTI, focusing on outcomes related to physical discomfort and outcomes linked to inflammatory states. The studies were often conducted during periods of increased symptom activity to understand how the medicine was observed in conditions associated with acute or disruptive episodes. Data show patterns related to how Lozid was evaluated in the observed populations when compared to a control or another medicine. A limitation is that follow-up durations were limited in some studies, meaning long-term effects are not fully established.


Evidence in special populations

Research has examined Lozid in studies involving patient groups whose bodies may process medicines differently, such as children and older adults. These studies applied in research contexts involving fluctuating or unstable symptoms. Research in older adults and those with impaired kidney or liver function monitored outcomes to understand whether Lozid was associated with changes in outcomes related to systemic or functional imbalance. It is important to note that sample sizes were modest in some of these special population studies, and data for certain groups, such as pregnant or breastfeeding populations, remain insufficient. Subgroup findings are uncertain where evidence quality varies across studies.

Frequently Asked Questions (FAQ)

Common questions about Lozid (FAQ)

Q: Is Lozid generally safe for older adults?

A: Studies and official information indicate that clinical trials included patients aged 65 and older. No clinically significant overall differences in effectiveness or safety were reported when comparing these older patients to younger adult patients.

Q: Is it true that Lozid is not recommended for people with heart conditions?

A: According to the official product information, Lozid is part of a treatment strategy for high blood pressure, including in patients with Left Ventricular Hypertrophy (enlarged heart). However, regulatory documents state that caution is specifically advised for use in patients with severe congestive heart failure.

Q: What kind of studies support the use of Lozid?

A: Official documentation for Lozid details results from controlled clinical trials, typically lasting 6 to 12 weeks. These studies compared the Losartan and Hydrochlorothiazide combination against a placebo (an inactive substance) and against each of the individual components alone.

Q: Can Lozid be taken on an empty stomach?

A: Regulatory documents state the tablets may be administered without regard to the timing of meals, meaning it can be taken independently of food intake. This applies whether the stomach is empty or not.

Q: Can people with a history of kidney problems use Lozid?

A: Official information indicates that use is approached with caution for patients with pre-existing kidney problems, as instances of worsening kidney function have been reported. It is strictly contraindicated (must not be used) in combination with Aliskiren for patients with moderate to severe renal impairment.

Q: Is Lozid known to be a long-term treatment option?

A: High blood pressure is a condition that requires continuous management. As such, treatment with the medicine is typically managed long-term to help sustain control of the condition.

Q: Does Lozid contain any ingredients that are similar to other common medicines?

A: Yes, one of the components, Hydrochlorothiazide, is a thiazide diuretic. This is a class of medicine that is chemically related to sulfonamide non-antibiotics, which are widely established chemical entities.

Q: How quickly does Lozid typically start working?

A: Official information regarding pharmacokinetics indicates that the Losartan component is absorbed quickly, reaching its maximum concentration in the blood within about one hour. However, the full intended effect of lowering blood pressure is typically measured over several weeks of continuous therapy.

Q: Are there any common foods or drinks to avoid while taking Lozid?

A: Regulatory documents advise that patients avoid the use of salt substitutes that contain potassium. This is because the Losartan component may be associated with an increase in the body’s potassium levels.

Q: Can Lozid affect my energy levels during the day?

A: According to the official product information, tiredness (fatigue) is listed as an adverse reaction that was reported during clinical trials.

Q: Is Lozid known to cause any significant changes in weight?

A: Unexplained weight gain or swelling has been reported as an adverse reaction. Official information states that this may signal a potential change in kidney function.

Q: Does taking Lozid mean I need to avoid sun exposure?

A: Regulatory safety communications mention that the hydrochlorothiazide component is associated with increased sensitivity to sunlight (photosensitivity). Protection from the sun is advised, as long-term use has been associated with a small increased risk of non-melanoma skin cancer.

Q: Can Lozid cause difficulty sleeping?

A: Official documents list difficulty sleeping (insomnia) and other sleep disorders as adverse reactions that have been reported during clinical use.

Q: Has Lozid been studied in children or adolescents?

A: Research has been conducted involving the Losartan component in pediatric patients 6 years of age and older to treat high blood pressure. However, doses above a certain limit have not been studied in children.

Q: Is Lozid considered a controlled substance?

A: Official drug listing information confirms that Lozid (Losartan Potassium and Hydrochlorothiazide) is not scheduled under the Controlled Substances Act (CSA) and is therefore not considered a controlled substance.

Q: Do patients typically use Lozid for a few weeks or a few months?

A: Since Lozid is prescribed for high blood pressure, which is a chronic condition, patients generally use it for the long term. This contrasts with medicines prescribed for short-term courses of a few weeks.

Q: Is there a maximum time frame that Lozid is generally used for?

A: Official guidance indicates that for managing chronic high blood pressure, the medicine is generally intended for long-term use. There is no maximum time frame specified for stopping the medicine based purely on duration.

Q: Does research indicate Lozid has any long-term side effects?

A: The hydrochlorothiazide component is associated with a small increased risk of developing non-melanoma skin cancer with long-term use. For this reason, official guidance mentions the need for skin protection from the sun.

Q: Do the official documents mention any effects of Lozid on mood?

A: Yes, official labeling lists changes in mood, specifically anxiety and depression, as adverse reactions that have been reported during clinical use.

Q: Are there specific patient groups that should use Lozid with caution?

A: Official product information describes that caution is applied when prescribing the medicine to patient groups with liver problems, severe congestive heart failure, or those who are volume depleted (such as from severe diarrhea or vomiting).

Q: Is Lozid a treatment or a cure for the condition it treats?

A: According to official information from regulatory bodies, the medicine will not cure high blood pressure. Rather, it is a treatment intended to help control the high blood pressure.

How should Lozid be stored and disposed of?

Storage and Disposal of Lozid (Losartan Potassium and Hydrochlorothiazide)

The storage of Lozid tablets is governed by regulatory requirements to ensure product integrity.


Storage Conditions

The medication must be stored at controlled room temperature, maintaining 20 C to 25 C (68 F to 77 F), with permitted excursions to 30 C (86 F). The tablets must be protected from light and excessive moisture. Keep the product in the original, tightly closed container and do not freeze.

Safety and Disposal

The medicine must be kept out of the reach of children and pets.

Official disposal guidance recommends using a drug take-back program for unused or expired tablets. If a take-back program is unavailable, non-flushable medicines may be mixed with an unappealing substance, placed in a sealed container, and discarded in the household trash, following local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lozid found in:

A-Z Index: